Aktuelle Kardiologie 2013; 2(6): 401-408
DOI: 10.1055/s-0033-1351080
Georg Thieme Verlag KG Stuttgart · New York

Update: ICD und CRT

Update ICD and CRT
M. Vöhringer
R. F. Bosch
› Author Affiliations
Further Information

Publication History

Publication Date:
17 December 2013 (online)


Die Behandlung mit einem ICD oder einem CRT-Device hat sich zu einer etablierten, breit angewandten kardiologischen Therapie entwickelt. Sowohl in der Sekundärprophylaxe nach hämodynamisch relevanter Kammertachykardie als auch in der Primärprophylaxe, insbesondere bei herzinsuffizienten Patienten, ist der signifikante Effekt eines ICD auf die Mortalität gesichert. Ebenso hat die CRT einen signifikanten Effekt auf Morbidität und Mortalität gezeigt – und dies bei immer mehr Patientengruppen, z. B. im Falle einer Herzinsuffizienz im Stadium NYHA II oder einer schrittmacherinduzierten Dyssynchronie. LSB-Morphologie und QRS-Dauer sind aber die wesentlichen Prädiktoren für einen Therapieerfolg geblieben. Wichtige Innovationen umfassen die Entwicklung rein subkutan implantierbarer ICDs und kabelloser Aggregate, die Verkleinerung der Aggregate, Verbesserung der Batterietechnik, neue Algorithmen zur Vermeidung inadäquater Schocks, MRT-Tauglichkeit sowie Fernabfrage und Fernmonitoring. All dies trägt zu besserem Patientenkomfort und Therapieerfolg bei.


The implantation of an ICD or a CRT has evolved as a well-established and prevalent therapy. The significant impact of an ICD on mortality is well proven in secondary prevention and also in primary prevention, especially in patients with heart failure. CRT as well has shown a significant effect on morbidity and mortality in patients with heart failure and prolonged QRS-interval. This is shown for increasing subgroups of patients as recently for patients in NYHA II and patients with dyssynchrony through a conventional pacemaker. But LBB-morphology and QRS-duration remain the main predictors of therapy response. New developments include the subcutaneous ICD, leadless pacers, improved battery technology, new algorithms to avoid inadaequate shocks, MR-compatibility and telemonitoring of the devices. All this will further improve patientsʼ convenience and effectiveness of ICD and CRT therapy.

  • Literatur

  • 1 John Camm A, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the ‘enigma’?. Europace 2010; 12: 1063-1069
  • 2 Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004; 19: 26-30
  • 3 Epstein AE, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: e350-e408
  • 4 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
  • 5 Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
  • 6 Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883
  • 7 Barsheshet A, Moss AJ, Huang DT et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012; 59: 2075-2079
  • 8 Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death–executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006; 27: 2099-2140
  • 9 Al-Majed NS, McAlister FA, Bakal JA et al. Meta-analysis: Cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011; 154: 401-412
  • 10 Tang AS, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2395
  • 11 Gold MR, Thebault C, Linde C et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012; 126: 822-829
  • 12 Moss AJ, Hall WJ, Cannom DS et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338
  • 13 Brignole M, Auricchio A, Baron-Esquivias G et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34: 2281-2329
  • 14 Ruschitzka F, Abraham WT, Singh JP et al. EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395-1405
  • 15 Sipahi I, Carrigan TP, Rowland DY et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011; 171: 1454-1462
  • 16 Sipahi I, Chou JC, Hyden M et al. Effect of qrs morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. Am Heart J 2012; 163: 260-267.e3
  • 17 Khan FZ, Virdee MS, Palmer CR et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012; 59: 1509-1518
  • 18 Hayes DL, Boehmer JP, Day JD et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8: 1469-1475
  • 19 Wilton SB, Leung AA, Ghali WA et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: A systematic review and meta-analysis. Heart Rhythm 2011; 8: 1088-1094
  • 20 Poole JE, Gleva MJ, Mela T et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: Results from the replace registry. Circulation 2010; 122: 1553-1561
  • 21 Boriani G, Gardini B, Diemberger I et al. Meta-analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on all-cause mortality and hospitalizations. Eur J Heart Fail 2012; 14: 652-660
  • 22 Martin DO, Lemke B, Birnie D et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm 2012; 9: 1807-1814
  • 23 Auricchio A, Delnoy PP, Regoli F et al. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace 2013; 15: 1191-1197
  • 24 Weiss R, Knight BP, Gold MR et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013; 128: 944-953
  • 25 Bardy GH, Smith WM, Hood MA et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363: 36-44
  • 26 Bosch RF, Villena P, Wanner A et al. Telemetrie bei implantierbaren devices: Was ist nötig, was ist sinnvoll?. Aktuel Kardiol 2012; 1: 309-318
  • 27 Varma N, Michalski J, Epstein AE et al. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-Up (TRUST) trial. Circ Arrhythm Electrophysiol 2010; 3: 428-436
  • 28 Landolina M, Perego GB, Lunati M et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: The evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 2012; 125: 2985-2992
  • 29 Crossley GH, Boyle A, Vitense H et al. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: The value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 2011; 57: 1181-1189
  • 30 Thijssen J, Borleffs CJ, van Rees JB et al. Implantable cardioverter-defibrillator longevity under clinical circumstances: An analysis according to device type, generation, and manufacturer. Heart Rhythm 2012; 9: 513-519
  • 31 Hauser RG, Abdelhadi R, McGriff D et al. Deaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm 2012; 9: 1227-1235
  • 32 Moss AJ, Schuger C, Beck CA et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367: 2275-2283
  • 33 Peterson PN, Varosy PD, Heidenreich PA et al. Association of single- vs. dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA 2013; 309: 2025-2034